Phathom Pharmaceuticals, Inc.
PHAT
$10.58
-$0.21-1.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 16.32% | 25.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 16.32% | 25.32% | |||
| Cost of Revenue | 23.55% | 22.87% | |||
| Gross Profit | 15.29% | 25.68% | |||
| SG&A Expenses | -6.18% | -39.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.95% | -34.85% | |||
| Operating Income | 61.18% | 74.52% | |||
| Income Before Tax | 29.44% | 60.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 29.44% | 60.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 29.44% | 60.46% | |||
| EBIT | 61.18% | 74.52% | |||
| EBITDA | 61.63% | 74.70% | |||
| EPS Basic | 29.85% | 60.96% | |||
| Normalized Basic EPS | 29.82% | 60.97% | |||
| EPS Diluted | 29.85% | 60.96% | |||
| Normalized Diluted EPS | 29.82% | 60.97% | |||
| Average Basic Shares Outstanding | 0.57% | 1.28% | |||
| Average Diluted Shares Outstanding | 0.57% | 1.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||